Company Profile - NGM Biopharmaceuticals Inc

Introduction

NGM Biopharmaceuticals Inc (NGM Bio) operates as a clinical-stage bio pharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases and ophthalmic diseases. The company’s pipeline products include NGM707, NGM831, NGM438, NGM120, NGM621, MK-3655 and Aldafermin. Its NGM707 is a novel dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript and NGM831 is the potential to fight tumors by shifting myeloid cells from a suppressive state to a stimulatory state and promote anti-tumor activity. The company’s biologic's platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.